Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy

ACS Nano ◽  
2021 ◽  
Author(s):  
Jiwoong Choi ◽  
Man Kyu Shim ◽  
Suah Yang ◽  
Hee Sook Hwang ◽  
Hanhee Cho ◽  
...  
2020 ◽  
Author(s):  
busenur Aslanoglu ◽  
Ilya Yakavets ◽  
Vladimir Zorin ◽  
Henri-Pierre Lassalle ◽  
Francesca Ingrosso ◽  
...  

Computational tools have been used to study the photophysical and photochemical features of photosensitizers in photodynamic therapy (PDT) –a minimally invasive, less aggressive alternative for cancer treatment. PDT is mainly based by the activation of molecular oxygen through the action of a photoexcited sensitizer (photosensitizer). Temoporfin, widely known as mTHPC, is a second-generation photosensitizer, which produces the cytotoxic singlet oxygen when irradiated with visible light and hence destroys tumor cells. However, the bioavailability of the mostly hydrophobic photosensitizer, and hence its incorporation into the cells, is fundamental to achieve the desired effect on malignant tissues by PDT. In this study, we focus on the optical properties of the temoporfin chromophore in different environments –in <i>vacuo</i>, in solution, encapsulated in drug delivery agents, namely cyclodextrin, and interacting with a lipid bilayer.


2020 ◽  
Vol 3 (6) ◽  
pp. 1900200
Author(s):  
Ching‐Hsin Huang ◽  
Natalie Mendez ◽  
Oscar Hernandez Echeagaray ◽  
Joi Weeks ◽  
James Wang ◽  
...  

2021 ◽  
Vol 1040 ◽  
pp. 61-67
Author(s):  
Anna B. Vlasenko ◽  
Vadim V. Bakhmetyev ◽  
Sergey V. Mjakin

Photodynamic therapy (PDT) is a promising modern method for treatment of oncological, bacterial, fungal and viral diseases. However, its application is limited to diseases with superficial localization since the body tissues are not transparent for visible light. To address this problem and extend PDT application to abdominal diseases, an enhanced method of X-ray photodynamic therapy (XRPDT) is suggested, involving X-ray radiation easily penetrating the body tissues. The implementation of this approach requires the development of a pharmacological drug including a photosensitizer stimulated by visible light to yield active oxygen and a nanosized phosphor converting X-ray radiation into visible light with the wavelength required for the photosensitizer activation. This study is aimed at obtaining X-ray stimulated phosphors with nanosized particles suitable for XRPDT application. For this purpose, Y2O3:Eu phosphors were synthesized via hydrothermal processing of the corresponding mixed acetate followed by annealing. To prevent from the undesirable agglomeration of the particles in the course of hydrothermal synthesis and subsequent annealing, different techniques were used, including rapid thermal annealing (RTA), microwave annealing and addition of finely dispersed pyrogenic silica (aerosil) to the phosphor. The microwave annealing was carried out using a special installation including a resonance chamber for maintaining a standing wave of microwave radiation. The performed research allowed the determination of hydrothermal processing optimal duration affording the synthesis of phosphors with the highest luminescence brightness. The application of microwave annealing is found to provide phosphors with a more perfect crystal structure compared with RTA. The developed method of Y2O3:Eu phosphor synthesis involving pyrogenic silica addition to the autoclave allowed the preparation of samples with the amorphous structure and significantly reduced the particle size without a considerable decrease in the luminescence brightness. The particle size of the phosphor synthesized with aerosil addition is less than 100 nm that allows its implementation in pharmacological drugs for XRPDT.


Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 5912
Author(s):  
Angèle Luby ◽  
Marie-Clotilde Alves-Guerra

Over the past decade, advances in cancer immunotherapy through PD1–PDL1 and CTLA4 immune checkpoint blockade have revolutionized the management of cancer treatment. However, these treatments are inefficient for many cancers, and unfortunately, few patients respond to these treatments. Indeed, altered metabolic pathways in the tumor play a pivotal role in tumor growth and immune response. Thus, the immunosuppressive tumor microenvironment (TME) reprograms the behavior of immune cells by altering their cellular machinery and nutrient availability to limit antitumor functions. Today, thanks to a better understanding of cancer metabolism, immunometabolism and immune checkpoint evasion, the development of new therapeutic approaches targeting the energy metabolism of cancer or immune cells greatly improve the efficacy of immunotherapy in different cancer models. Herein, we highlight the changes in metabolic pathways that regulate the differentiation of pro- and antitumor immune cells and how TME-induced metabolic stress impedes their antitumor activity. Finally, we propose some drug strategies to target these pathways in the context of cancer immunotherapy.


Sign in / Sign up

Export Citation Format

Share Document